CranioView

Cover Block

PUBLIC

Name	CranioView
Tagline	Wearable, noninvasive device using ocular ultrasound and machine learning to monitor intracranial pressure.
Headquarters	San Francisco, CA, United States
Founded	2020
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed

Links

PUBLIC

• Website: https://www.cranioview.com
• LinkedIn: https://www.linkedin.com/company/cranioview-inc

Executive Summary

PUBLIC CranioView is developing a wearable, noninvasive device that uses ocular ultrasound and machine learning to continuously monitor intracranial pressure (ICP), a technology that, if proven, could address a critical unmet need in neurocritical care [cranioview.com]. Founded in 2020, the company is an early-stage healthtech venture that has disclosed minimal public information, operating with an estimated team of one to ten employees [Prospeo]. Its core proposition is a hardware-plus-software solution that aims to replace invasive, high-risk monitoring procedures with a simpler, continuous alternative for patients with acute neurological injuries.

The founding team is led by Gil Herrnstadt, a CEO with a background in medical robotics and translational research [LinkedIn]. A co-founder is identified as a physician with experience in healthcare consulting, suggesting a blend of clinical and commercial perspectives, though the full team composition is not detailed in public profiles [cranioview.com]. The company has acknowledged receiving support from UCLA and participation in the Magnify Incubator at CNSI, but specific funding amounts, lead investors, and a detailed capitalization table are not publicly available [F6S].

For investors, the next 12 to 18 months will be defined by the company's ability to transition from concept to clinical validation. Key milestones to watch include securing regulatory clearances, initiating pilot studies with hospital partners, and providing the first public data on the device's accuracy and clinical utility. The absence of such data, coupled with a lack of press coverage or disclosed customer deployments, currently places the company in a high-risk, high-potential category where technical execution is the primary determinant of value.

Data Accuracy: YELLOW -- Core product claims are confirmed from the company website; team and funding details are partially corroborated by third-party databases but lack independent verification.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

Company Overview

PUBLIC

CranioView, Inc. was founded in 2020, a timing that places its genesis squarely within a period of heightened investor and clinical interest in remote patient monitoring and non-invasive diagnostics [F6S]. The company maintains its headquarters in San Francisco, California, a location consistent with its positioning in the medical device and healthtech venture ecosystem [LinkedIn]. The founding narrative, as presented on its website, centers on a team of physicians and engineers dedicated to advancing neurocritical care, with the explicit goal of creating life-saving solutions for patients with neurological injuries [cranioview.com].

Key milestones from the company's early development are limited to foundational and programmatic events. Its participation in the Magnify Incubator at the California NanoSystems Institute (CNSI) at UCLA represents a significant early-stage milestone, providing access to laboratory space, mentorship, and an institutional affiliation [cranioview.com]. The company has also secured seed-stage capital, with investor interest noted from UCLA among others, though the specific round details remain undisclosed [F6S].

Operational scale is modest, with public sources estimating the team size at between one and ten employees [Prospeo]. The company's public footprint is minimal, with no press releases, regulatory announcements, or detailed funding disclosures available from named-publisher sources as of this report's publication. This suggests a focus on stealth development and prototype validation rather than commercial launch activities.

Data Accuracy: YELLOW -- Founding year and incubator participation confirmed by company website; headquarters and team size corroborated by LinkedIn and Prospeo. Funding details and specific milestones lack independent public verification.

Product and Technology

MIXED CranioView’s core proposition is a hardware-software system designed to replace an invasive clinical procedure with a wearable monitor. The company’s flagship product is a wearable, noninvasive device that uses ocular ultrasound and machine learning to continuously monitor intracranial pressure (ICP) [cranioview.com]. The intended use case is specific: patients with neurological injuries in neurocritical care settings, where continuous ICP monitoring is critical but currently requires drilling a small hole in the skull to place a sensor [cranioview.com].

The technical approach centers on transcranial Doppler ultrasonography (TCD-US). The device images blood flow in the ophthalmic artery, central retinal artery, and posterior ciliary arteries, using these signals as a proxy for pressure inside the skull [cranioview.com]. A machine learning component is then applied to interpret the ultrasound data and produce an accurate ICP reading. The company describes the system as self-calibrating, which, if validated, would address a significant hurdle for noninvasive monitoring by reducing the need for frequent manual adjustments against an invasive gold standard [cranioview.com].

Public materials frame the product strictly as a development-stage medical device. There are no disclosed specifications regarding battery life, form factor, or connectivity. Similarly, the status of regulatory submissions, clinical validation, or any pilot deployments with hospital partners is not publicly available. The technology stack beyond the described ultrasound and ML components is inferred from the team’s background in medical robotics and biomedical engineering, but not detailed in any source.

Data Accuracy: YELLOW -- Product claims are consistent across the company website and several third-party databases, but technical details and development status are not corroborated by independent clinical or engineering publications.

Market Research

PUBLIC The market for noninvasive intracranial pressure monitoring is driven by a clinical imperative to reduce the mortality and morbidity associated with traumatic brain injuries, where the standard of care remains an invasive, risky procedure.

Total addressable market figures specific to noninvasive ICP monitors are not publicly available in cited sources. The broader market for neuromonitoring devices, a relevant analog, was valued at $2.1 billion globally in 2021 and is projected to reach $3.4 billion by 2028, according to a report by Grand View Research [Grand View Research, 2022]. This growth is driven by the high incidence of neurological disorders and traumatic brain injuries (TBI). The serviceable obtainable market for a device like CranioView's would be a narrower segment focused on acute neurocritical care, where an estimated 1.7 million Americans sustain a TBI annually, and over 50,000 die from these injuries [CDC]. Even a small penetration rate into this acute care segment would represent a significant commercial opportunity.

Key demand drivers are clinical and economic. The current gold standard for ICP monitoring requires drilling a burr hole through the skull to place a catheter or sensor, a procedure carrying risks of hemorrhage, infection, and cerebrospinal fluid leak that can limit its use and duration [Journal of Neurosurgery]. A reliable noninvasive alternative could expand monitoring to a wider patient population, including those in resource-limited settings or for whom invasive monitoring is contraindicated. Furthermore, continuous, rather than intermittent, monitoring could enable earlier intervention to prevent secondary brain injury, potentially improving outcomes and reducing length of stay in intensive care units, a major cost driver.

Regulatory pathways and reimbursement structures are critical macro forces. Any novel device would require FDA clearance, likely through the 510(k) or De Novo pathways, a process demanding robust clinical validation data [FDA]. Success also hinges on securing favorable reimbursement codes from the Centers for Medicare & Medicaid Services and private payers, a process that can lag behind regulatory approval. The market is also adjacent to, and could be substituted by, advancements in other neuromonitoring modalities, such as advanced EEG, near-infrared spectroscopy, or transcranial Doppler systems used for different diagnostic purposes.

Global Neuromonitoring Devices Market (Analogous) 2021 | 2.1 | $B
Projected Market 2028 | 3.4 | $B

The projected growth in the broader neuromonitoring sector, while not a direct proxy, indicates sustained investment and demand for technologies that improve neurological care, providing a favorable backdrop for specialized entrants.

Data Accuracy: YELLOW -- Market sizing is based on an analogous sector report from a named publisher; specific TAM for noninvasive ICP monitoring is not confirmed.

Competitive Landscape

MIXED CranioView enters a clinical monitoring segment defined by a stark choice between an invasive gold standard and a collection of non-invasive technologies that have struggled to achieve widespread clinical adoption.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
CranioView	Wearable, non-invasive ICP monitor using ocular ultrasound & ML for neurocritical care.	Seed; investor UCLA; part of Magnify Incubator at CNSI (UCLA). Funding amount undisclosed. [PUBLIC]	Self-calibrating device based on transcranial Doppler ultrasonography (TCD-US) imaging specific ocular arteries. [cranioview.com]

The competitive map for intracranial pressure monitoring is stratified by clinical risk tolerance and technological approach. The incumbent standard is the invasive intraventricular catheter, a procedure requiring neurosurgical insertion but providing direct, continuous pressure readings. This method, supplied by large medtech firms like Integra LifeSciences and Medtronic, owns the critical care market due to its established accuracy despite the infection and hemorrhage risks. The non-invasive segment is populated by challengers employing various techniques, including tympanic membrane displacement, optic nerve sheath diameter ultrasound, and transcranial Doppler. CranioView's named competitor, CranioSense, operates in this same non-invasive category, though its specific technical approach is not detailed in public sources. Adjacent substitutes include advanced neuroimaging (CT, MRI) for spot checks and other multi-modal neuromonitoring systems that infer pressure from secondary physiological signals.

CranioView's claimed edge rests on its specific technical pathway,transcranial Doppler ultrasonography focused on the ophthalmic artery and its branches,combined with a machine learning layer for continuous interpretation. The company's physician-engineer founding team provides a translational research background that could be advantageous for navigating early clinical validation. However, this edge is highly perishable; it is contingent on unproven clinical accuracy and has not yet been fortified by peer-reviewed data, regulatory clearance, or intellectual property that is visible in public records. The participation in the UCLA incubator offers access to academic clinical networks, a common early-stage advantage that must be converted into formal pilot studies to have lasting value.

The company's most significant exposure is to the entrenched clinical workflow and the high validation bar of the neuro-ICU. Any non-invasive device must demonstrate reliability comparable to the invasive catheter to change physician behavior, a hurdle that has stalled prior attempts. CranioSense and other undisclosed rivals are racing toward the same clinical and regulatory milestones. Furthermore, CranioView's lean operational scale and undisclosed funding raise questions about its capital runway to finance the expensive clinical trials required for FDA clearance, a process where better-funded competitors could outpace them.

The most plausible 18-month scenario is one of increased segmentation within the non-invasive field, driven by early clinical data readouts. A winner will likely emerge from the first company to publish compelling results from a prospective clinical trial in a reputable journal, securing a lead in clinician mindshare and partnership discussions. A loser in this period would be a company that fails to progress beyond benchtop prototypes or small feasibility studies, remaining in the "interesting concept" category while others advance toward regulatory submission. For CranioView, the path to becoming the winner hinges on converting its academic incubator position into a structured clinical validation program with published findings.

Data Accuracy: YELLOW -- Subject's positioning is confirmed by company sources; one competitor is named but with minimal corroborating detail. Broader market context is established from standard clinical practice.

Opportunity

PUBLIC If CranioView successfully commercializes its noninvasive intracranial pressure monitor, the prize is a dominant position in a critical, high-stakes segment of neurocritical care monitoring, a market historically constrained by invasive and risky procedures.

The headline opportunity is to become the standard-of-care, noninvasive monitoring device for traumatic brain injury (TBI) and stroke patients in intensive care units. The cited evidence shows the company is targeting a clear, unmet clinical need: continuous ICP monitoring is vital for managing severe neurological injuries, but the current gold standard requires drilling a hole in the skull, which carries infection and hemorrhage risks and limits monitoring duration [cranioview.com]. By developing a wearable device that uses ocular ultrasound, CranioView is pursuing a solution that could be applied earlier, used longer, and deployed in more clinical settings than invasive monitors. The company's physician-engineer founding team and its incubation within UCLA's Magnify Incubator at CNSI lend plausibility to the technical and clinical development required to reach this standard-of-care outcome [cranioview.com] [F6S].

Multiple, concrete growth paths exist beyond the initial ICU application. The technology's noninvasive nature opens scenarios where monitoring could expand into step-down units, emergency departments, or even pre-hospital settings, dramatically increasing the addressable patient population.

Scenario	What happens	Catalyst	Why it's plausible
Standard of Care in Neuro-ICUs	The device becomes a mandatory piece of equipment for monitoring severe TBI and stroke patients, replacing invasive monitors for a majority of cases.	Successful FDA clearance and publication of a pivotal clinical trial demonstrating non-inferiority to invasive ICP monitoring.	The clinical demand for a safer, continuous monitor is well-established. The company's focus on a specific, high-acuity setting provides a clear beachhead [cranioview.com].
Expansion to Neurological Wards & ERs	Monitoring expands beyond the ICU to lower-acuity hospital wards and emergency rooms for patients with moderate head injuries, enabling earlier intervention.	A follow-on, simplified version of the device designed for easier application by non-specialist staff.	The core value proposition,avoiding an invasive procedure,is even more compelling in settings where placing an invasive monitor is often deemed too risky or impractical.
Long-term Monitoring for Chronic Conditions	The wearable form factor enables outpatient monitoring for conditions like idiopathic intracranial hypertension, creating a recurring revenue model from device usage.	Partnerships with neurology clinics and payer reimbursement for at-home monitoring codes.	The company describes its product as a "wearable" device, implying a design intended for extended use [cranioview.com]. This aligns with a broader trend toward decentralized, continuous health monitoring.

Compounding for CranioView would manifest as a clinical data moat. Each device deployment would generate unique, continuous ICP waveforms paired with patient outcomes. This dataset would be proprietary and critical for refining the machine learning algorithms that interpret the ultrasound signals, improving accuracy over time. Furthermore, early adoption in leading academic medical centers (a plausible first step given the UCLA connection) could create a reference customer effect, easing sales into community hospitals and establishing clinical guidelines that embed the technology into standard protocols.

The size of the win can be framed by looking at the market for invasive ICP monitoring devices and the valuation of comparable medical device disruptors. The global market for intracranial pressure monitoring devices was valued at approximately $1.7 billion in 2023 and is projected to grow, driven by the rising incidence of neurological disorders [Grand View Research, 2024]. A company that successfully captures a significant portion of this market by displacing invasive procedures could command a valuation in the hundreds of millions to low billions of dollars, based on precedent. For example, Integra LifeSciences, a major player in neurosurgery tools including ICP monitoring, has a market capitalization in the multi-billion dollar range. If CranioView's "Standard of Care in Neuro-ICUs" scenario plays out, capturing even 20% of the high-acuity monitoring segment could translate into a company worth several hundred million dollars (scenario, not a forecast).

Data Accuracy: YELLOW -- The core product description and target market are confirmed by the company's website. Market size and growth projections are cited from a named industry report. The specific growth scenarios and valuation comparables are analyst inferences based on the confirmed product premise and standard market dynamics.

Sources

PUBLIC

1. [cranioview.com] About | https://www.cranioview.com/about

2. [LinkedIn] CranioView, Inc. | https://www.linkedin.com/company/cranioview-inc

3. [Prospeo] CranioView Email Format & Contact Info | https://prospeo.io/c/cranioview-email-format

4. [F6S] CranioView | F6S | https://www.f6s.com/company/cranioview

5. [Grand View Research, 2022] Global Neuromonitoring Devices Market Size Report | https://www.grandviewresearch.com/industry-analysis/neuromonitoring-devices-market

6. [CDC] Traumatic Brain Injury & Concussion | https://www.cdc.gov/traumaticbraininjury/index.html

7. [Journal of Neurosurgery] Complications of invasive intracranial pressure monitoring | https://thejns.org/view/journals/j-neurosurg/aop/article-10.3171-2023.3.JNS23230/article-10.3171-2023.3.JNS23230.xml

8. [FDA] Medical Device Development | https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/medical-device-development

9. [Grand View Research, 2024] Intracranial Pressure Monitoring Devices Market Size Report | https://www.grandviewresearch.com/industry-analysis/intracranial-pressure-monitoring-devices-market